Changes of the WHO classification of lymphoid neoplasms in the context of the 2016 revision

1. Cazzola M. Introduction to a review series: The 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues. Blood 2016; 127(20): 2361-2364.

2. Swerdlow SH, Campo E, Harris NL et al, eds. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2008.

3. Swerdlow SH, Campo E, Pileri SA et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127(20): 2375-2390.

4. Scott DW, Wright GW, Williams PM et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 2014; 123(8): 1214-1217.

5. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103(1): 275-282.

6. Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol 2014; 11(1): 12-23.

7. Nicolae A, Pittaluga S, Abdullah S et al. EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment. Blood 2015; 126(7): 863-872.

8. Dojcinov SD, Venkataraman G, Raffeld M et al. EBV positive mucocutaneous ulcer - a study of 26 cases associated with various sources of immunosuppression. Am J Surg Pathol 2010; 34(3): 405-417.

9. Swerdlow SH. Diagnosis of „double hit“ diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC. Hematology Am Soc Hematol Educ Program 2014; 2014(1): 90-99.

10. Johnson NA, Savage KJ, Ludkovski O et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009; 114(11): 2273-2279.

11. Campo E. MYC in DLBCL: partners matter. Blood 2015; 126(22): 2439-2440.

12. Johnson NA, Slack GW, Savage KJ et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone. J Clin Oncol 2012; 30(28): 3452-3459.

13. Horn H, Ziepert M, Becher C et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 2013; 121(12): 2253-2263.

14. Green TM, Young KH, Visco C et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with Rituximab plus Cyclophosphamide, Doxorubicin, Vincristine and Prednisone. J Clin Oncol 2012; 30(28): 3460-3467.

15. Schmitz R, Young RM, Ceribelli M et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012; 490(7418): 116-120.

16. Ferreiro JF, Morscio J, Dierickx D et al. Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern. Haematologica 2015; 100(7): 275-279.

17. Salaverria I, Philipp C, Oschlies I et al. Molecular mechanisms in Malignant lymphomas network project of the Deutsche Krebshilfe; German high-grade lymphoma study group; Berlin-Frankfurt-Munster-NHL Trial Group. Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. Blood 2011; 118(1): 139-147.

18. Tiacci E, Trifonov V, Schiavoni G et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011; 364(24): 2305-2315.

19. Waterfall JJ, Arons E, Walker RL et al. High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias. Nat Genet 2014; 46(1): 8-10.

20. Treon SP, Xu L, Yang G et al. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Engl J Med 2012; 367(9): 826-833.

21. Swerdlow SH, Kuzu I, Dogan A et al. The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing. Virchows Arch 2016; 468(3): 259-275.

22. Roccaro AM, Sacco A, Jimenez C et al. C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. Blood 2014; 123(26): 4120-4131.

23. Furtado M, Rule S. Indolent mantle cell lymphoma. Haematologica 2011; 96(8): 1086–1088.

25. Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest 2012; 122(10): 3416-3423.

26. Bea S, Valdes-Mas R, Navarro A et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci 2013; 110(45): 18250-18255.

27. Nodit L, Bahler DW, Jacobs SA, et al. Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes. Hum Pathol 2003; 34(10): 1030-1034.

28. Balhárek T, Plank L. Úloha patológa v manažmente chronickej lymfocytovej leukémie. Onkológia 2014; 9(6): 365–370.

29. Hallek, M., Cheson, B.D., Catovsky, D. et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute – Working Group 1996 guidelines. Blood 2008; 111(12): 5446-5456.

30. Rawstron AC, Shanafelt T, Lanasa MC et al. Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL). Cytometry B Clin Cytom 2010; 78(suppl 1): S19-S23.

31. Gine E, Martinez A, Villamor N et al. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (“accelerated” chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica 2010; 95(9): 1526-1533.

32. Gradowski JF, Sargent RL, Craig FE et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma with cyclin D1 positive proliferation centers do not have CCND1 translocations or gains and lack SOX11 expression. Am J Clin Pathol 2012; 138(1): 132-139.

33. Rossi D, Rasi S, Spina V et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 2013; 121(8): 1403-1412.

34. Baliakas P, Hadzidimitriou A, Sutton LA et al. European Research Initiative on CLL (ERIC). Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 2015; 29(2): 329-336.

35. Louissaint A, Ackerman AM, Dias-Santagata D et al. Pediatric-type nodal follicular lymphoma: an indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement. Blood 2012; 120(12): 2395-2404.

36. Schmatz AI, Streubel B, Kretschmer-Chott E et al. Primary follicular lymphoma of the duodenum is a distinct mucosal/submucosal variant of follicular lymphoma: a retrospective study of 63 cases. J Clin Oncol 2011; 29(11): 1445-1451.

37. Katzenberger T, Kalla J, Leich E et al. A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions in the chromosomal region 1p36. Blood 2009; 113(5): 1053-1061.

38. Jegalian AG, Eberle FC, Pack SD et al. Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma. Blood 2011; 118(11): 2976-2984.

39. Carvajal-Cuenca A, Sua LF, Silva NM et al. In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. Haematologica 2012; 97(2): 270-278.

40. Iqbal J, Wright G, Wang C et al. Lymphoma Leukemia Molecular Profiling Project and the International Peripheral T-cell Lymphoma Project. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 2014; 123(19): 2915-2923.

41. Parilla Castellar ER, Jaffe ES, Said JW et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 2014; 124(9): 1473-1480.

42. Agnelli L, Mereu E, Pellegrino E et al. European T-Cell Lymphoma Study Group. Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large cell lymphoma. Blood 2012; 120(6): 1274-1281.

43. Miranda RN, Aladily TN, Prince HM et al. Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol 2014; 32(2): 114-120.

44. Deleeuw RJ, Zettl A, Klinker E et al. Whole genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes. Gastroenterology 2007; 132(5): 1902-1911.

45. Chan JK, Chan AC, Cheuk W et al. Type II enteropathy-associated T-cell lymphoma: a distinct aggressive lymphoma with frequent γδ T-cell receptor expression. Am J Surg Pathol 2011; 35(10): 1557-1569.

46. Perry AM, Warnke RA, Hu Q et al. Indolent T-cell lymphoproliferative disease of the gastrointestinal tract. Blood 2013; 122(22): 3599-3606.

47. Lemonnier F, Couronne L, Parrens M et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood 2012; 120(7): 1466-1469.

48. Nicolae A, Pittaluga S, Venkataraman G et al. Peripheral T-cell lymphomas of follicular T-helper cell derivation with Hodgkin/Reed-Sternberg cells of B-cell lineage: both EBVpositive and EBV-negative variants exist. Am J Surg Pathol 2013; 37(6): 816-826.

49. Guitart J, Weisenburger DD, Subtil A et al. Cutaneous gd T-cell lymphomas: a spectrum of presentations with overlap with other cytotoxic lymphomas. Am J Surg Pathol 2012; 36(11): 1656-1665.

50. Petrella T, Maubec E, Cornillet-Lefebvre P et al. Indolent CD8-positive lymphoid proliferation of the ear: a distinct primary cutaneous T-cell lymphoma? Am J Surg Pathol 2007; 31(12): 1887-1892.

51. Garcia-Herrera A, Colomo L, Camos M et al. Primary cutaneous small/medium CD4+ T-cell lymphomas: a heterogeneous group of tumors with different clinicopathologic features and outcome. J Clin Oncol 2008; 26(20): 3364-3371.